ArticleMedical decision making : an international journal of the Society for Medical Decision Making
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.
Article in Medical decision making : an international journal of the Society for Medical Decision Making. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is individualized medicine more cost-effective? A systematic review.PharmacoEconomics · 2014Pooled it
- Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Trial
- Differences in Weight Loss Between Persons on Standard Balanced vs Nutrigenetic Diets in a Randomized Controlled Trial.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Trial
- Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management.Health services insights · 2025Article
- Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.Biomedicines · 2024Review
- Impact of patient nationality on the severity of early side effects after radiotherapy.Journal of cancer research and clinical oncology · 2023Article
- Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia.Cancer reports (Hoboken, N.J.) · 2023Article
- Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.Pharmaceutics · 2020Review
- One size does not fit all - Patterns of vulnerability and resilience in the COVID-19 pandemic and why heterogeneity of disease matters.Brain, behavior, and immunity · 2020Review
- Cost-effectiveness of precision medicine: a scoping review.International journal of public health · 2019Article
- Precision medicine and monoclonal antibodies: breach of promise?Croatian medical journal · 2019Article
- Genomic research and the cancer clinic: uncertainty and expectations in professional accounts.New genetics and society · 2019Article
- Applying Mental Model Methods to Characterize Understanding of Gene-Environment Influences: The Case of Podoconiosis in Ethiopia.Critical public health · 2019Article
- The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Pharmaceutical research · 2017Review
- Defining the Clinical Value of a Genomic Diagnosis in the Era of Next-Generation Sequencing.Annual review of genomics and human genetics · 2016Review
- Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.Journal of community genetics · 2016Article
- Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges.Frontiers in pharmacology · 2016Article
- Economic evaluations of personalized medicine: existing challenges and current developments.Pharmacogenomics and personalized medicine · 2015Review
- Dashboard systems: implementing pharmacometrics from bench to bedside.The AAPS journal · 2014Review
- Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.Genetics in medicine : official journal of the American College of Medical Genetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Personalized medicine is health care that tailors interventions to individual variation in risk and treatment response. Although medicine has long strived to achieve this goal, advances in genomics promise to facilitate this process. Relevant to present-day practice is the use of genomic information to classify individuals according to disease susceptibility or expected responsiveness to a pharmacologic treatment and to provide targeted interventions. A symposium at the annual meeting of the Society for Medical Decision Making on 23 October 2007 highlighted the challenges and opportunities posed in translating advances in molecular medicine into clinical practice. A panel of US experts in medical practice, regulatory policy, technology assessment, and the financing and organization of medical innovation was asked to discuss the current state of practice and research on personalized medicine as it relates to their own field. This article reports on the issues raised, discusses potential approaches to meet these challenges, and proposes directions for future work. The case of genetic testing to inform dosing with warfarin, an anticoagulant, is used to illustrate differing perspectives on evidence and decision making for personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.